SOUTH SAN FRANCISCO--(BUSINESS WIRE)--True North Therapeutics, a clinical stage biotechnology company developing novel therapies for Complement-mediated rare diseases, today announced the launch of the COMPASS Registry (www.compassregistry.org), a patient registry created by True North Therapeutics in collaboration with PatientCrossroads, for patients with Cold Agglutinin Disease (CAD) (and other autoimmune hemolytic anemias). The COMPASS Registry is designed to build a deeper understanding of the natural history of CAD, characterize clinical biomarkers and engage early with patients and physicians to help accelerate development of new therapeutics. Currently there are no FDA approved therapies available for CAD, a disease in which autoantibodies target and destroy red blood cells, causing anemia, fatigue and potentially fatal thrombosis.
“The COMPASS Registry is a leading example of how a patient registry can serve as an important and powerful tool for collecting data on a defined group of patients who share a particular disease”
“There are no approved medicines for patients living with CAD such as myself,” said Betty Usdan, founder of www.coldagglutinindisease.org, an on-line community for CAD patients. “With the creation of the COMPASS Registry, patients with CAD have the opportunity to play a more active role in their health care.”
“The COMPASS Registry is a leading example of how a patient registry can serve as an important and powerful tool for collecting data on a defined group of patients who share a particular disease,” said Kyle Brown, Chief Executive Officer and Founder of PatientCrossroads. “Through the COMPASS Registry, True North can facilitate a high level of collaboration between patients and physicians to help increase disease understanding and improve clinical outcomes for patients.”
True North’s lead drug candidate, TNT009, is currently in Phase 1b clinical development for the treatment of CAD. The company has applied its expertise in drug development targeting the Complement pathway of the immune system to treat autoimmune hemolytic anemias, including CAD.
“We are honored to support the creation of the COMPASS Registry which was established to capture valuable patient-provided medical data on CAD and other autoimmune hemolytic anemias, to help advance the understanding of these diseases,” said Adam Rosenthal, Vice President of Corporate Development at True North Therapeutics. “Through this registry, we hope to increase awareness of the symptoms and progression of CAD, so that physicians and patients can better recognize disease severity and, together, we can advance development of new medicines for patients.”
About Cold Agglutinin Disease (CAD)
CAD is an autoimmune hemolytic anemia in which autoantibodies target and destroy red blood cells, causing anemia, fatigue and potentially fatal thrombosis. The prevalence of primary CAD is approximately twenty per million. There are limited treatment options available and many of these patients, despite therapy, have moderate to severe anemia.
About TNT009
TNT009 is a first-in-class monoclonal antibody that selectively inhibits the Classical Complement pathway by targeting C1s, a serine protease within the C1-complex in the Complement pathway of the immune system. TNT009 thereby prevents downstream disease processes involving phagocytosis, inflammation, and cell lysis. With a unique mechanism of action and high target specificity, TNT009 selectively inhibits disease processes in the Classical Complement pathway while maintaining the important immune surveillance provided by the Alternative Complement Pathway and Lectin Complement Pathway. TNT009 is currently in clinical development for the treatment of Cold Agglutinin Disease (CAD), a rare disease in hematology. TNT009 is also being evaluated in three other complement-mediated rare diseases that share the same basic underlying mechanism in the hematology, transplant and dermatology settings.
About True North Therapeutics
True North Therapeutics is a clinical stage biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in rare diseases with high unmet need. The company’s lead drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway. True North’s antibody drug development is focused on the treatment of rare diseases mediated by the Complement system in hematology, transplantation, and dermatology. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.
The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com
